Summary

A reservoir of risk in the treatment of dyslipidemia calls for optimization of statin treatment, which involves monitoring of response and compliance and adjustment of dose as needed. Also, other therapeutic approaches are needed. Niacin and fibrates are questionable options. Ezetimibe, PCSK9 inhibitors, mipomersen, and lomitapide have potential merit.